The Falcons inked him to a six-year, $72 million dollar deal with $27.3 million guaranteed.Ryan’s contract received more scrutiny, because its numbers were close to the contracts of Peyton Manning, Tom Brady, and Ben Roethlisberger, just to name a few. Not to mention, Ryan’s contract is higher than those of David Garrard, Donovan McNabb, andDrew Brees, all proven quarterbacks.“He doesn’t have to play a down in the NFL and he already has his money,” Goodell said during a Q&A session during a function at the Chautauqua Institution. “Now, with the economics where they are, the consequences if you don’t evaluate that player, you can lose a significant amount of money.”You are 100 percent correct Mr Goodell. Why should a young kid, who has never stepped on the field in the NFL, make more than a proven veteran? It’s, to quote Goodell again, “ridiculous.”Many have pitched the idea that the NFL should bring in a rookie salary cap, much like the NBA's slot-system. Their rookie pay scale assigns salaries by their draft position (the first overall pick receives more than the second pick, the second more than the third, etc...).The only problem is that Gene Upshaw, president of the NFL Player’s Union, doesn’t back it.

He claims that by capping rookie salaries, veterans will miss out on bigger deals.“[I’m] concerned that keeping rookie salaries too cheap could price veterans out of jobs, especially those who make one of the varying minimum salaries,” said Upshaw, “We don’t want to get into a position where the league is keeping four or five rookies because it’s cheaper than keeping one or two veterans.”While there is credence to what Upshaw says, in the end, teams will keep talent no matter what age they are. In fact, most teams seem to be cutting veterans when they have to deal with the high-paid rookie.And in some cases, it comes back to bite them.Just look at the Chicago Bears. They traded Thomas Jones, a proven running back, to the Jets in order to put high-paid draft pick Cedric Benson on the field. Now the Bears are paying for it in the form of a cap hit.So, maybe if the commish starts to speak out on big deals, Upshaw will have no choice but to step up and work out an agreement to please both sides.Kudos Goodell! This is one of the many issues the NFL has to solve. This article is also featured on The Red Zone Report. DUBLIN--(Business Wire)--Research and Markets( http://) hasannounced the addition of the "Biogen Idec IMS Company Profile" company profileto their offering. This Company Profile gives you the authoritative insight into a company at astrategic and local level. The strategy analysis gives you an insight into the following:* M&A * Regional strategies * Therapeutic focus * R&D strategy * Licensing activities * Commentary on future prospects, including brokers' overviews * Interview with a key person (where available), including quotes and opinions * Forecasting table (top 30 companies only), showing events with major potentialimpactCompany Sales Performance:* Financial review * Latest results * Sales by geographical region & leading country * Sales by country and subsidiary * Analysis commentsThe section shows: www* Summary table of products facing patent expiry.

* Breakdown by relevant therapy area, within which, each product is discussedunder the following headings: general, licensing, patents, clinical data,lifecycle management, competition and analysts' forecasts/comments.Comprehensive details of the projects that the company has in its R&D pipelineincluding:* Research pipeline summary table * Introduction to the R&D activities of the company. * Breakdown by relevant therapy area, within which, each project is detailed (upto 2 A4 pages), including information on clinical status and analysts'forecasts. * Quotes from senior personnel gleaned from conferences may also be included inthis section when available.Key figures* Sales by business segment. * Sales by geographical region.IMS sales data* Pharmaceutical sales by geographical region and leading countries * Top 5 third level therapeutic classes.

* Leading international products * Pharmaceutical sales analysis by ageFor more information visit http:// IMS Health Laura WoodSenior Fax from USA: 646-607-1907Fax from rest of the world: +353-1-481-1716 Copyright Business Wire 2009. * Q1 EPS 56 cts; Wall St view 33 cts Stocks  |  China * Same-restaurant sales fell 6.6 pct at Bistro locations * Sees FY 2009 EPS from continuing ops $1.45-$1.50 (Adds details on forecast) NEW YORK, April 22 (Reuters) - P.F. Chang's China BistroInc (PFCB.O) posted a higher-than-expected quarterly profit onWednesday, helped by cost cost controls at itsChinese-themed restaurants. The company also increased its full-year earnings forecast,based on improved operating margins at its restaurants.